What did @kmwisf_2.0 actually say?
The creator is asking a genuine question, not making a claim, which is actually refreshing. They say they were prescribed "the pill version of Wegovy" through Hims and want to know whether it works. Their goal: drop from 190 to 145 pounds, combining the medication with exercise. They specifically mention the 1.5 mg dose and want real-world confirmation before committing.
This is a reasonable question from someone who has already been through a clinical intake process. What they received is almost certainly oral semaglutide, which exists as a branded product called Rybelsus, though the formulation Hims dispenses may differ. The creator does not make exaggerated claims, does not promise results to anyone, and does not recommend a specific dose to followers. Full credit for that.
Does the science back this up?
Yes, oral semaglutide does work for weight loss, but with meaningful caveats around dose and absorption. The short answer is that it is less effective than injectable semaglutide at comparable clinical benchmarks, and the dose they mention is on the lower end of what trials have tested for weight management specifically.
The OASIS 1 trial (Knop et al., 2023, The Lancet) tested oral semaglutide up to 50 mg daily in people with obesity and found a mean body weight reduction of around 15% over 68 weeks. That is a meaningful result. However, the FDA-approved Rybelsus tops out at 14 mg for type 2 diabetes, not obesity, and is not approved for weight management in the way injectable Wegovy is. A 1.5 mg dose is well below even the standard diabetes maintenance dose of 7-14 mg. Oral semaglutide also has notoriously poor bioavailability, roughly 1% under ideal fasting conditions, compared to nearly complete absorption with subcutaneous injection (Buckley et al., 2018, Clinical Pharmacokinetics).
What did they get wrong (or right)?
The creator did not get much factually wrong because they asked a question rather than asserting facts. But there are two things worth flagging. First, calling it "the pill version of Wegovy" is technically imprecise. Wegovy is injectable semaglutide. The oral form is Rybelsus, a separate product with a different delivery mechanism, different approved indications, and different absorption profile. They are not interchangeable, and equating them understates how different the pharmacokinetics actually are.
Second, the 1.5 mg figure matters. If that is genuinely what was prescribed, it sits at the low end. Rybelsus is typically started at 3 mg for one month as a gastrointestinal tolerance dose, then escalated to 7 mg and potentially 14 mg. A 1.5 mg dose from a telehealth platform could be a compounded oral semaglutide product, which would not be bioequivalent to Rybelsus and carries its own regulatory uncertainty. FormBlends does not endorse compounded semaglutide as equivalent to branded products. The creator should confirm exactly what formulation they have.
What should you actually know?
If you are considering oral semaglutide for weight loss, here is what the data actually supports. Injectable semaglutide outperforms oral versions in head-to-head comparisons on weight reduction. That said, oral semaglutide is not a placebo. The PIONEER trials (Rodbard et al., 2019, Diabetes Care) showed it beats placebo meaningfully for blood sugar and, to a lesser degree, weight in people with type 2 diabetes.
A 45-pound goal, which is what this creator is targeting, is ambitious but not unrealistic for someone using GLP-1 therapy with consistent exercise and a calorie deficit. That said, results vary significantly based on diet adherence, baseline metabolic health, and how the drug is absorbed. Oral semaglutide must be taken on an empty stomach with a small amount of plain water, at least 30 minutes before eating, to get even close to adequate absorption. Missing that window repeatedly will reduce efficacy substantially.
- Oral semaglutide bioavailability is approximately 1%, making consistent dosing conditions essential
- The OASIS 1 trial showed up to 15% weight reduction with high-dose oral semaglutide, but at doses far above 1.5 mg
- A 1.5 mg dose may be a starting titration or a compounded product. Clarify this with your prescriber.
- Combining GLP-1 therapy with resistance training helps preserve lean muscle mass during weight loss (Lundgren et al., 2021, Obesity)